NEWS RELEASE – FOR IMMEDIATE RELEASE 23rd May 2001

- COPY STARTS -

CAMBRIDGE DRUG DISCOVERY LIMITED ENTERS INTO COLLABORATION WITH MILLENNIUM PHARMACEUTICALS INC TO ADVANCE A BROAD RANGE OF MILLENNIUM'S NOVEL GENOMIC TARGETS

Cambridge Drug Discovery Limited (Cambridge Drug Discovery) and Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that they have entered into a two-year collaborative agreement to accelerate Millennium's pre-clinical research programmes derived from a broad range of novel genomic targets. This new alliance builds on the successful completion of previous discovery projects. Millennium will have access to Cambridge Drug Discovery's molecular pharmacology expertise, customised assay development technologies as well as the Company's fully automated high-throughput screening capabilities. The alliance will involve the development of a substantial number of new proprietary assays and therapeutically relevant secondary assays.

"This is an important new collaboration for us in many exciting new areas of novel biology that will allow us to work with Millennium on a wide range of proprietary drug targets and assist them in the identification and development of novel chemical compounds," commented Dr Mark Treherne, Chief Executive Officer of Cambridge Drug Discovery. "We are delighted that Millennium has decided to build on our previous collaborations and are pleased to be able to work alongside such a prominent biopharmaceutical company."

For further information, please contact:

Cambridge Drug Discovery Limited

Dr Mark Treherne, CEO, Cambridge Drug Discovery Ltd, Cambridge Science Park, Milton Road,

Cambridge CB4 0FG, UK

Tel: +44 (0) 1223 723222 Fax: +44 (0) 1223 723223 Email: info@camdd.co.uk Website: http://www.camdd.co.uk

Millennium Pharmaceuticals Inc

Maureen Suda, Sr. Manager Corporate Communications, 215 First Street, Cambridge, MA 02114,

USA

Tel: +1 617 551 2959 Fax: +1 617 374 7788

Email: suda@mpi.com Website: http://www.mlnm.com

Noonan Russo Limited

Don O'Sullivan, Account Manager, Noonan Russo Ltd, 15 Basinghall Street, London

EC2V 5BR

Tel: +44 (0) 207 7264452 Fax: +44 (0) 207 7264453

Email: DO'Sullivan@noonanrusso.com Website: http://www.noonanrusson.com

Note to Editors

About Cambridge Drug Discovery

Cambridge Drug Discovery Ltd provides a range of biological technologies, expertise and resources to accelerate the drug discovery process. The Company's platform strength stems from its target discovery, assay development, efficient high-throughput screening and integrated informatics capabilities that Cambridge Drug Discovery exploits to enhance its partners' drug discovery programmes. The company is based in Cambridge, UK, and was set up in 1997. Cambridge Drug Discovery is the trading entity of Cambridge Drug Discovery Holdings Ltd.

About Millennium Pharmaceuticals Inc

Millennium, a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering personalized medicine. Through the industrialization of this gene-to-patient platform, Millennium is also striving to accelerate the process of drug discovery and development. Headquartered in Cambridge, Mass., Millennium currently employs more than 1,300 people.